Literature DB >> 10831716

Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.

M A Farrell1, H P McAdams, J E Herndon, E F Patz.   

Abstract

PURPOSE: To determine the accuracy of 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) in the evaluation of regional lymph nodes in patients with stage I non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS: Imaging and clinical findings obtained during 5 years in 84 patients (mean age, 66 years) were reviewed. Patients had thoracic computed tomographic findings of stage I NSCLC, an FDG PET study, and histopathologic proof of lung cancer. At the time of diagnosis, disease stage was assigned on the basis of FDG PET results and was compared with the histopathologic stage to determine the accuracy of PET.
RESULTS: When PET stage was compared with histopathologic stage, the disease in 72 (86%) patients was accurately staged with PET, understaged in two (2%), and overstaged in 10 (12%). The overall sensitivity, specificity, and positive and negative predictive values for PET of regional lymph nodal metastases were 82%, 86%, 47%, and 97%, respectively.
CONCLUSION: FDG PET enables accurate staging of regional lymph node disease in patients with stage I NSCLC. A negative PET scan in these patients suggests that mediastinoscopy is unnecessary and that these patients can proceed directly to thoracotomy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10831716     DOI: 10.1148/radiology.215.3.r00jn29886

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  13 in total

Review 1.  18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.

Authors:  G Laking; P Price
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

2.  Evolution and science, progress and change.

Authors:  Frank C Detterbeck
Journal:  Thorax       Date:  2007-08       Impact factor: 9.139

3.  Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis.

Authors:  Jingbo Wang; Kathy Welch; Luhua Wang; Feng-Ming Spring Kong
Journal:  Clin Lung Cancer       Date:  2011-11-03       Impact factor: 4.785

4.  Multidisciplinary Evaluation of Patients With Suspected Lung Cancer.

Authors:  Kristy Bauman; Douglas Arenberg
Journal:  Clin Pulm Med       Date:  2010-01-01

5.  Mediastinoscopy: trends and practice patterns in the United States.

Authors:  Krishna S Vyas; Daniel L Davenport; Victor A Ferraris; Sibu P Saha
Journal:  South Med J       Date:  2013-10       Impact factor: 0.954

Review 6.  Inoperable localized stage I and stage II non-small-cell lung cancer.

Authors:  Eric L Gressen; Walter J Curran
Journal:  Curr Treat Options Oncol       Date:  2002-02

7.  18F-FDG PET/CT in mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosis-endemic country: consideration of lymph node calcification and distribution pattern to improve specificity.

Authors:  Jeong Won Lee; Bom Sahn Kim; Dong Soo Lee; June-Key Chung; Myung Chul Lee; Soonhag Kim; Won Jun Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-09       Impact factor: 9.236

Review 8.  Staging lymph node metastases from lung cancer in the mediastinum.

Authors:  Mario D Terán; Malcolm V Brock
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

Review 9.  Positron emission tomography scanning for the diagnosis and management of lung cancer.

Authors:  Bruce R Line; Charles S White
Journal:  Curr Treat Options Oncol       Date:  2004-02

10.  Advances in radiological staging of non-small cell lung cancer (NSCLC).

Authors:  S C Rankin
Journal:  Cancer Imaging       Date:  2004-02-14       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.